2023
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor
McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsFemaleGene AmplificationHumansLeiomyosarcomaMAP Kinase Kinase 4MiceMice, SCIDNeoplasm Recurrence, LocalPelvic NeoplasmsUterine NeoplasmsConceptsUterine leiomyosarcomaPDX modelsGain of functionMedian overall survivalPhase I trialOral gavage dailyVivo activityTumor growth inhibitionTumor volume differencesTumor cell proliferationOverall survivalTolerable toxicityI trialOral treatmentTreatment cohortsGavage dailyAggressive tumorsSCID miceULMS patientsPK studiesTumor samplesWestern blotCell proliferationControl vehicleLeiomyosarcoma
2012
Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: Review of surgical technique, complications, and outcome
Andikyan V, Khoury-Collado F, Gerst S, Talukdar S, Bochner B, Sandhu J, Abu-Rustum N, Sonoda Y, Barakat R, Chi D. Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: Review of surgical technique, complications, and outcome. Gynecologic Oncology 2012, 126: 346-350. PMID: 22555107, DOI: 10.1016/j.ygyno.2012.04.034.Peer-Reviewed Original ResearchConceptsAnterior pelvic exenterationPelvic exenterationTotal vaginectomyPelvic recurrencePostoperative complicationsGenitourinary malignanciesSurgical techniqueNegative pathologic marginsPreliminary survival dataMajor postoperative complicationsMedian tumor sizeEvidence of diseaseRate of readmissionComplete surgical resectionTotal pelvic exenterationCentral pelvic recurrencePrimary tumor sitePancreatic recurrenceOperative mortalityOncologic outcomesSurgical resectionMedian ageCase seriesPathologic marginsTumor sizeExtended pelvic resections for recurrent or persistent uterine and cervical malignancies: An update on out of the box surgery
Andikyan V, Khoury-Collado F, Sonoda Y, Gerst S, Alektiar K, Sandhu J, Bochner B, Barakat R, Boland P, Chi D. Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: An update on out of the box surgery. Gynecologic Oncology 2012, 125: 404-408. PMID: 22285844, DOI: 10.1016/j.ygyno.2012.01.031.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedFemaleHumansMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPelvic ExenterationSurvival RateTreatment OutcomeUterine Cervical NeoplasmsUterine NeoplasmsConceptsExtended pelvic resectionR0 resectionPostoperative complicationsOverall survivalCervical malignancyPelvic resectionPositive pathologic marginsUterus/cervixMajor postoperative complicationsOutcomes of patientsComplete gross resectionKaplan-Meier methodMedian tumor diameterDays post surgeryEn bloc resectionMajor vascular structuresPrimary tumor siteUterus/Perioperative mortalityCommon morbidityGross resectionMedian agePeripheral neuropathyPost surgeryPelvic abscess